# US 2025/0164358 A1 · Affinity capture of extracellular matrix bodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164358 A1
- Document ID: US20250164358A1
- Status: Published application
- Kind: A1
- Application number: 18/929,353
- Filed: 2024-10-28
- Published: 2025-05-22
- Earliest claimed: 2022-04-28
- Assignees: Aufbau Medical Innovations Limited
- Applicants: Aufbau Medical Innovations Ltd.
- Inventors: John T. G. PENA; John IRWIN; Farideh MEHRAEIN-GHOMI; James Murray MITCHELL; Harmon Lawrence REMMEL
- Web page: https://patentgrep.com/patent/US20250164358A1

## CPC

- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- B01D 15/02: with moving adsorbents
- B01D 15/3804: {Affinity chromatography}
- B01D 15/3885: {using electrical or magnetic means}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

This invention relates to methods for separating, isolating and/or enriching extracellular matrix bodies in a biological fluid. More particularly, this invention discloses methods for isolating and detecting extracellular matrix bodies from a biological sample as medical information and/or for use in diagnosis and prognosis of disease. The methods include immuno-affinity capture of extracellular matrix bodies.

## Claims

### Claim at position 1

1-48. (canceled)

### Claim 49

A process for separating, isolating or enriching extracellular matrix bodies in a biological fluid, the process comprising capturing the extracellular matrix bodies on a substrate, optionally wherein:
a) the substrate is:
i) a solid and comprises one or more immobilized capture moieties for binding and immobilizing the extracellular matrix bodies;
ii) of any shape in the form of a bead, a gel, a magnetic bead, a paramagnetic bead, a plate, a well, a membrane, a particle, a sheet, or a fiber; and/or
iii) composed of an inorganic material, a polymeric material, an organic material, a metal, a glass, or a combination thereof;
b) the capturing comprises:
i) contacting the biological fluid with the substrate; and/or
ii) adding capture moieties to the biological fluid and contacting the biological fluid with the substrate;
c) the biological fluid is:
i) incubated with the substrate, and wherein the substrate comprises capture moieties; and/or
ii) the biological fluid is processed before the capturing on the substrate to remove cells and cell debris; and/or
d) the process further comprises:
i) washing the substrate to remove the biological fluid and any non-bound components from the substrate;
ii) eluting the immobilized extracellular matrix bodies from the substrate, wherein the extracellular matrix bodies have a principal size from about 1 micrometer to 200 micrometers, or from about 4 micrometers to 200 micrometers; and/or
iii) tagging the extracellular matrix bodies in the biological fluid for capturing on the substrate, optionally wherein the tagging uses epitope tags, affinity tags, fluorescent tags, or a combination thereof.

### Claim 50 (depends on 49)

The process of claim 49, wherein the capture moieties bind to any of a protein, an extracellular matrix protein, a polypeptide, a lipid molecule, a lipoparticle, a carbohydrate, or a nucleic acid of the extracellular matrix bodies, optionally wherein the capture moieties are antibodies, metal ions, or dyes.

### Claim 51 (depends on 49)

The process of claim 49, wherein at least a majority of or substantially all of the extracellular matrix bodies are captured from the biological fluid, optionally with an absence of cells.

### Claim 52 (depends on 49)

The process of claim 49, wherein the captured extracellular matrix bodies are a biomarker or contain biomarkers for medical, diagnostic or prognostic information.

### Claim 53 (depends on 49)

The process of claim 49, further comprising additional separating, isolating or enriching of the eluted extracellular matrix bodies by microfluidic separation, affinity chromatography, centrifugation, differential centrifugation, density gradient centrifugation, mesh filtration, diafiltration, tangential flow filtration, membrane filtration, immuno-affinity capture, magnetic bead capture, size exclusion chromatography, electrophoresis, AC electrokinetics, and combinations thereof.

### Claim 54 (depends on 49)

The process of claim 49, wherein the extracellular matrix bodies are captured using capture moieties with affinity to one or more biomarkers selected from the group consisting of: IGHG4, PIGR, IGHA1, IGLV4-60, IGHD, HBB, HPR, IGKV1-6, IGHM, HBA1, CFB, LPA, F12, B4E1Z4, IGHV3-33, SERPINF2, IGHV2-70D, JCHAIN, IGHV6-1, TLN1, FGA, THBS1, IGHA2, CFH, IGHV5-51, IGHV4-39, IGKV3-20, IGHV3-53, ITIH1, A2M, CFD, CRP, CD5L, LGALS3BP, IGKV3-15, PON1, ORM1, SLC4A1, APOC4-APOC2, IGKV2-29, FGB, IGLC2, IGHV3OR15-7, IGHA2, IGLV8-61, IGHV3-21, IGLV4-69, IGLV1-44, C4B, C7, ACTB, IGLV3-21, PGLYRP2, IGHV1-18, IGKV2D-28, IGKV2-24, FBLL1, IGKC, IGHV3-9, ITIH4, AHSG, AGT, IGHV1-69, IGHV1-3, SPTA1, IGLV2-11, IGKV1D-33, LRG1, IGHV3-72, FGG, APOC1, LYZ, IGKV1-5, IGKV1-27, IGHV1-46, C1R, IGKV1-16, C4BPB, IGFALS, IGKV4-1, PF4, IGHV1OR15-1, IGKV1D-12, IGKV2-30, IGHV3-74, SERPING1, IGHV3-43D, APOH, C1S, PLG, IGLV3-9, IGHV3-49, APOL1, SERPINC1, CFP, AMBP, C6, IGHV3-38, IGKV2D-29, IGHV4-28, ADIPOQ, IGHV3-73, IGHG3, CPN1, PROS1, IGHG2, IGHV7-4-1, F2, IGLV3-10, IGLV6-57, CFH, ALB, HRG, FN1, C3, C1QB, F5, GC, IGLV1-51, PLTP, EFEMP1, SERPINA5, CPN2, IGKV1-13, IGKV3-11, IGLV3-25, SHBG, FCGBP, AZGP1, ING4, APOD, HPX, CD14, APOE, IGLV3-19, C9, APOM, IGKV3-7, IGLL5, ITIH2, IGKV1-9, ECM1, IGHV3OR16-12, CLEC3B, APOB, CFHR2, IG-unk, IGKV1D-39, TTR, FBLN1, IGHV3-64, KLKB1, LUM, VTN, C5, PZP, SERPIND1, F13B, HABP2, APOA2, SERPINA6, IGLL1, APOA4, IGHV3-66, IGKV6D-21, IGHV3-13, ALB, IGKV1D-37, IGKV1-17, ITIH3, APCS, CPB2, CFI, C1QC, SERPINF1, TGFB1, C8G, IGHV2-5, APOA1, F9, CLU, KNG1, IGLV1-40, SERPINA1, C8A, IGHG1, SELENOP, HP, IGHV4-38-2, SERPINA4, LBP, ORM2, FN1, F10, APOC3, CFHR1, ATRN, B2M, VWF, F13A1, AFM, GPX3, FCN3, RBP4, C8B, SERPINA3, PRG4, C4A, SAA2-SAA4, SERPINA7, CP, A1BG, C2, IGHV1-2, HGFAC, FETUB, GSN, SERPINA1, C1QA, C4BPA, IGKV3OR2-268, HSPG2, FGG, FGA, FGB, APOC1, LYZ, ANG, IGFBP5, C1QB, F5, H1-4, HBA1, KRT10, H1-0, QSOX1, HABP2, KRT9, KRT2, VTN, H4C1, KRT1, C8B, C1QA, MTHFD2, CFHR1, ACTB, HRG, EEF1A1, H2AC4, MMP2, TIMP2, ATP5F1B, HGFAC, ENO1, HSPG2, COL18A1, APOE, CFH, RARRES2, SERPINA5, SAA4, PEBP4, C1QC, CHI3L1, PON1, CLU, SERPIND1, PCOLCE, C8A, APOM, APOA1, APOD, ECM1, SELENOP, SERPINA4, KNG1, C9, PROS1, CFHR2, SPON1, CLSTN1, APP, GPX3, RNASE1, IGFBP6, AL645922.1, ITIH2, C5, GSN, APOA2, RBP3, HP, C3, APOA4, C6, APLP2, TTR, and PLG.

### Claim 55 (depends on 49)

The process of claim 49, further comprising adding a reagent to the biological fluid, wherein the reagent is for precipitating the extracellular matrix bodies.

### Claim 56 (depends on 49)

The process of claim 49, wherein the extracellular matrix bodies when eluted and re-suspended are at least 5-fold, or at least 10-fold, or at least 100-fold enriched in concentration as compared to the biological fluid.

### Claim 57 (depends on 49)

The process of claim 49, wherein the extracellular matrix bodies are associated with a pathology or disease.

### Claim 58 (depends on 49)

The process of claim 49, wherein the biological fluid is any one of whole blood, blood plasma, blood serum, cerebrospinal fluid, vitreous, aqueous humor, breast milk, nipple aspirate, urine, saliva, sweat, tears, synovial fluid, pleural fluid, gastric fluid, peritoneal fluid, semen, amniotic fluid, lymph, bile, cerumen, chyle, chyme, endolymph, perilymph, exudates, feces, ejaculate, gastric acid, gastric juice, mucus, pericardial fluid, pus, rheum, sebum, serous fluid, smegma, sputum, synovial fluid, vaginal secretion, menstrual effluent, vomit, and combinations thereof.

### Claim 59 (depends on 49)

The process of claim 49, further comprising determining a level of a biomarker of the separated, isolated or enriched extracellular matrix bodies.

### Claim 60 (depends on 59)

The process of claim 59, wherein the biomarker is the level of the extracellular matrix bodies, or the level of a substance found in the extracellular matrix bodies, wherein the substance is a protein, a polypeptide, a lipid molecule, a lipoparticle, a carbohydrate, a nucleic acid molecule, or an expression level of a nucleic acid.

### Claim 61 (depends on 60)

The process of claim 60, wherein the level of the substance is determined by any of microscopy, immunostaining, fluorescence assay, chelate complexation, quantitative HPLC, spectrophotometry, antibody array, Western blot, immunoassay, immunoprecipitation, ELISA, LC-MS, LC-MRM, radioimmunoassay, mass spectrometry, 2D gel mass spectrometry, LC-MS/MS, RT-PCR, nucleic acid sequencing, next generation sequencing, multi-well automated versions thereof, and combinations thereof.

### Claim 62

A method for preparing a biological sample by distinguishing extracellular matrix bodies for a medical, diagnostic or prognostic use, the method comprising isolating extracellular matrix bodies from the biological sample, wherein the isolation involves capturing the extracellular matrix bodies on a substrate, and wherein the extracellular matrix bodies have a principal size from about 1 micrometer to 200 micrometers, or from about 4 micrometers to 200 micrometers.

### Claim 63 (depends on 62)

The method of claim 62, wherein the biological sample is composed of a bodily fluid, optionally wherein the bodily fluid is any of whole blood, blood plasma, blood serum, cerebrospinal fluid, vitreous, aqueous humor, breast milk, nipple aspirate, urine, saliva, sweat, tears, synovial fluid, pleural fluid, gastric fluid, peritoneal fluid, semen, amniotic fluid, lymph, bile, cerumen, chyle, chyme, endolymph, perilymph, exudates, feces, ejaculate, gastric acid, gastric juice, mucus, pericardial fluid, pus, rheum, sebum, serous fluid, smegma, sputum, synovial fluid, vaginal secretion, menstrual effluent, vomit, and combinations thereof.

### Claim 64 (depends on 62)

The method of claim 62, wherein the extracellular matrix bodies are isolated by any of microfluidic separation, affinity chromatography, centrifugation, differential centrifugation, density gradient centrifugation, mesh filtration, diafiltration, tangential flow filtration, membrane filtration, immuno-affinity capture, magnetic bead capture, size exclusion chromatography, electrophoresis, AC electrokinetics, and combinations thereof.

### Claim 65 (depends on 62)

The method of claim 62, wherein the capturing comprises adding capture moieties to the biological sample and contacting the biological sample with the substrate.

### Claim 66

A process for diagnosing, prognosing or monitoring a disease in a subject, the process comprising:
a) separating, isolating or enriching extracellular matrix bodies in a biological fluid sample of the subject, wherein the separation, isolation or enrichment involves capturing the extracellular matrix bodies on a substrate;
b) determining a level of one or more biomarkers based on the separated, isolated or enriched extracellular matrix bodies, wherein the biomarker is the level of the extracellular matrix bodies, or the level of a substance found in the extracellular matrix bodies, wherein the substance is a protein, a polypeptide, a lipid molecule, a lipoparticle, a carbohydrate, a nucleic acid molecule, or an expression level of a nucleic acid; and
c) comparing the level of the biomarkers to a reference level based on a control group of subjects, and diagnosing, prognosing or monitoring the disease in the subject.

### Claim 67 (depends on 66)

The process of claim 66, wherein the separated, isolated or enriched extracellular matrix bodies comprise biomarkers in the form of proteins, extracellular matrix proteins, polypeptides, lipids, lipoparticles, carbohydrates, nucleic acid molecules, DNA, or an expression level of a nucleic acid.

### Claim 68 (depends on 66)

The process of claim 66, comprising treating the subject for the disease by any one or more of surgery, drug therapy, therapeutic radiation, and chemotherapy.
